Insider · CIK 0002130384
James Dean Watson
Files at SCTX (Scribe Therapeutics, Inc.). First filing -, latest -.
In brief
James Dean Watson files SEC Form 4 as director at SCTX (Scribe Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Dean Watson has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +14,725 | $0.00 | $0 | 14,725 | Jul 27, 2026 |
Questions about James Dean Watson
Answered from the filings on this page, as of the latest one.
Is James Dean Watson buying or selling?
James Dean Watson has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Dean Watson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Dean Watson has 0.
Where does James Dean Watson file Form 4?
James Dean Watson has filed Form 4 at SCTX (Scribe Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.